Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2013 by Global Alliance for TB Drug Development.
Recruitment status was  Active, not recruiting
Information provided by (Responsible Party):
Global Alliance for TB Drug Development Identifier:
First received: December 21, 2011
Last updated: March 12, 2013
Last verified: March 2013